PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Philippe G. Nantermet

Serial No.:

To Be Assigned

Case No.: 21456YP

US Nat'l Filing Date:

December 22, 2005

Int'l Appl'n No.

PCT/US2004/020525

Int'l Filing Date:

25 June 2004

For:

PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS

FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT EXPRESS MAIL NO.

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed

Commissioner for Patents, P. O. Box 1450, Alexandria, Virginia 22313-1450

MAILED BY KORE Schepuse

10/562470

Page

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

References BB, CC, DD and EE were cited in the International Search Report during the International phase of this application. A copy of the International Search Report and Written Opinion of the International Searching Authority are enclosed.

Reference BB is an abstract of reference E; reference CC is an abstract of reference D; and reference DD is an abstract of reference C.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

drney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-0125

Date: December 22, 2005

IAP15 Rec'd PCT/PTO 22 DEC 2005
SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

S	ubstitute for form 1449A/PTO			COMPLETE IF KNOWN				
I	NFORMATION 1	DIS	CLOSURE	Application Number	To Be Assigned 10/56247			
STATEMENT BY APPLICANT				Filing Date	December 22, 2005			
				First Named Inventor	Philippe G. Nantermet			
			,	Group Art Unit	To Be Assigned			
	(use as many sheets	as n	ecessary)	Examiner Name	To Be Assigned			
Sheet	1	of	2	Attorney Docket Number	21456YP			

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY		

FOREIGN PATENT DOCUMENTS									
	G:.		Foreign Patent Documen	t	N. C.	Date of Publication of			
Examiner Initials*	Cite No.	Office Number		Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY			
	A		WO 89/04833	PCT	The Upjohn Company	06/01/1989			
В			WO 01/00665	PCT	Oklahoma Medical Research Foundation &	01/04/2001			
					The Board of Trustees of the				
					University of Illinois				
	С		WO 2003/072535	PCT	Elan Pharmaceuticals, Inc.	09/04/2003			
					& Pharmacia & Upjohn				
	D		EP 1 186 305	PCT	Schering Aktiengesellschaft	03/13/2002			
	Е		JP 02000129	PCT	Fujisawa	05/01/1990			
	F		WO 03/106405	PCT	Sunesis Pharmaceuticals, Inc.	12/24/2003			
	G		WO 2005/0053374	PCT	Sunesis Pharmaceuticals, Inc.	01/20/2005			

Examiner D	Date Considered	
--------------	--------------------	--

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IAP 15 Rec'd PCT/PTO 22 DEC 2001

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Applicant

Sut	ostitute for form 1449B/PTO			COMPLETE IF KNOWN				
	NFORMATION 1	DIS	CLOSURE	Application Number	To Be Assigned 90/569/17			
S'	TATEMENT DV	ΑĐ	DI ICANT	Filing Date	December 22, 2005			
STATEMENT BY APPLICANT				First Named Inventor	Philippe G. Nantermet			
			,	Group Art Unit	To Be Assigned			
	(use as many sheets	as n	ecessary)	Examiner Name	To Be Assigned			
Sheet	2	of	2	Attorney Docket Number	21456YP			

NON PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Examiner Initials* Cite Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.								
	AA	C. A. Coburn et al., "Identification of a Small Molecule Nonpeptide Active Site Beta-Secretase Inhibitor That Displays a Nontraditional Binding Mode for Aspartyl Proteases," J. Med. Chemistry, Vol. 47, pp. 6117-6119 (2004)							
	вв	E. Rubini et al., "Synthesis of Isosteric Methylene-Oxy Pseudodipeptide Analogues As Novel Amide Bond Surrogate Units," Tetrahedron, Vol. 42, No. 21, pp. 6039-6045 (1986)							
	СС	CAPLUS Abstract 113:40174							
	DD	CAPLUS Abstract 139:230480							
	EE	CAPLUS Abstract 136:232115							

Examiner Signature	*	Date Considered		

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.